Pharmaceutical

FDA approves IASO Bio’s IND for equecabtagene autoleucel

IASO Biotherapeutics has secured the US Food and Drug Administration (FDA) approval equecabtagene autoleucel (Eque-cel).

Aug 13, 2024 - 04:00
FDA approves IASO Bio’s IND for equecabtagene autoleucel
IASO Biotherapeutics has secured the US Food and Drug Administration (FDA) approval equecabtagene autoleucel (Eque-cel).
Read the original article

Tags:

Previous Article

FDA rejects Lykos MDMA therapy, asks for another Phase III trial

Next Article

Blue Earth and Seibersdorf expand radiopharmaceutical manufacture deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward

STAT+: After four patients died of gene therapy, Astell...

Nov 15, 2023

STAT+: ‘Stung’ by Pear’s bankruptcy, a state Medicaid program pauses on digital therapeutics

STAT+: ‘Stung’ by Pear’s bankruptcy, a state Medicaid p...

Jun 10, 2023

The fundamentals of developing parenteral drug products 

The fundamentals of developing parenteral drug products 

Nov 9, 2024